Discover the ELLIPTA inhaler

Clinical Studies

The ELLIPTA inhaler ease-of-use studies1,2

Inhalers did not contain active treatment.

At the conclusion of two 4-week clinical studies (1 in asthma [N=250] and 1 in COPD [N=266])

96 % of patients with asthma

demonstrated correct use and rated
the ELLIPTA inhaler easy to use

93 % of patients with COPD

demonstrated correct use and rated
the ELLIPTA inhaler easy to use

Learn which features of the ELLIPTA inhaler were preferred by patients with COPD

Features of the ELLIPTA Inhaler

Breath actuated

Requires no hand-breath coordination

Preloaded

Each inhaler contains 30 available doses

Single-step
dose activation

A dose is ready when the cover is opened fully. Counter automatically keeps track of remaining doses.

For more information, see the Instructions for Use in the Medication Guide or Patient Information for products delivered in the ELLIPTA inhaler.

 

See the medicines available in the ellipta inhaler

References: 1. Data on file, GSK. Study 201594. 2. Data on file, GSK. Study 201071.

Trademarks are owned by or licensed to the GSK group of companies.

1002527R0 April 2018